Arkansas is currently home to 734 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Lynn Institute of the Ozarks, Little Rock, Arkansas
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Investigative Site US307, Fort Smith, Arkansas
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
04/25/2024
Locations: Research Site, Little Rock, Arkansas
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782
Recruiting
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab (MK-3475A) administered subcutaneously (SC) over pembrolizumab (MK-3475) administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Highlands Oncology Group-Research Department ( Site 0133), Springdale, Arkansas
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Register for Updates
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States
NCT06026332
Recruiting
Multi-center, prospective non-interventional study to collect data on the early use of ADSTILADRIN in the US. Data will be collected from participants, caregivers and prescribing physicians in a real-world setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Ferring Investigational Site, Little Rock, Arkansas
Conditions: Bladder Cancer
Register for Updates
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 < 50%.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Research Site, Hot Springs National Park, Arkansas
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
NCT05936567
Recruiting
This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2024
Locations: Little Rock Allergy Asthma, Pa Clinical Research Center Lraac, Little Rock, Arkansas
Conditions: Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Register for Updates
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
NCT05861999
Recruiting
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered in pediatric participants with SMA and 2 SMN2 copies who previously received onasemnogene abeparvovec and experience a plateau or decline in function. Participants to be enrolled are children <2 years of age genetically diagnosed with SMA.
Gender:
All
Ages:
Between 3 months and 24 months
Trial Updated:
04/25/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Muscular Atrophy, Spinal
Register for Updates
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
NCT05861986
Recruiting
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children < 2 years of age genetically diagnosed with SMA.
Gender:
All
Ages:
Between 3 months and 24 months
Trial Updated:
04/25/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Muscular Atrophy, Spinal
Register for Updates
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
NCT05764161
Recruiting
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/25/2024
Locations: Northwest Arkansas Clinical Trials Center, Arkansas, Arkansas
Conditions: Prurigo Nodularis
Register for Updates
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
NCT05755438
Recruiting
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/25/2024
Locations: Johnson Dermatology, Fort Smith, Arkansas
Conditions: Prurigo
Register for Updates
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05620836
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Investigative Site US214, Arkansas, Arkansas
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates